King Pharmaceuticals Commences Phase III Clinical Trial Involving Binodenoson
Aderis Pharmaceuticals’ partner, King Pharmaceuticals, today announced that the Phase III trials of binodenoson, an adenosine A2A receptor agonist for cardiac pharmacologic stress-imaging, have been initiated with the dosing of the first patient.
Hopkinton, MA - Dec 7, 2003 - Aderis Pharmaceutical's partner for binodenoson, King Pharmaceuticals, initiated the Phase III trials to diagnose the presence and severity of coronary artery disease. Read the complete release from King.
"At Aderis, we are excited about the progress of our product candidates and their potential ability to improve quality of life for millions of people. We are committed to helping patients and investors understand our progress as we achieve corporate and clinical milestones."
-Kenneth L. Rice, Jr.,
Chief Commercial Officer, Aderis Pharmaceuticals
back to top
